-
1
-
-
33749017051
-
The quality of pharmacologic care for adults in the United States
-
Shrank WH, Asch SM, Adams J, Setodji C, Kerr EA, Keesey J, et al. The quality of pharmacologic care for adults in the United States. Med Care. 2006;44(10):936-45.
-
(2006)
Med Care
, vol.44
, Issue.10
, pp. 936-45
-
-
Shrank, W.H.1
Asch, S.M.2
Adams, J.3
Setodji, C.4
Kerr, E.A.5
Keesey, J.6
-
2
-
-
60549111800
-
Copayment levels and medication adherence: less is more
-
Choudhry NK. Copayment levels and medication adherence: less is more. Circulation. 2009;119(3):365-7.
-
(2009)
Circulation
, vol.119
, Issue.3
, pp. 365-7
-
-
Choudhry, N.K.1
-
3
-
-
33947331188
-
Value-based insurance design and the next generation of consumer-driven health care
-
DOI: 10.1377/hlthaff.26.2.w204
-
Brennan T, Reisman L. Value-9based insurance design and the next generation of consumer-driven health care. Health Aff(Millwood). 2007; 26(2):w204-7. DOI: 10.1377/hlthaff.26.2.w204.
-
(2007)
Health Aff(Millwood)
, vol.26
, Issue.2
-
-
Brennan, T.1
Reisman, L.2
-
4
-
-
0037849900
-
The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program
-
Cranor CW, Bunting BA, Christensen DB. The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc (Wash). 2003;43(2):173-84.
-
(2003)
J Am Pharm Assoc (Wash)
, vol.43
, Issue.2
, pp. 173-84
-
-
Cranor, C.W.1
Bunting, B.A.2
Christensen, D.B.3
-
6
-
-
84880600152
-
-
Unpublished paper
-
Chernew ME, Juster IA, Shah M, Wegh A, Rosenberg S, Rosen A, et al. The financial effects of a value based insurance design program. 2009. Unpublished paper.
-
(2009)
The financial effects of a value based insurance design program.
-
-
Chernew, M.E.1
Juster, I.A.2
Shah, M.3
Wegh, A.4
Rosenberg, S.5
Rosen, A.6
-
7
-
-
84880591480
-
-
To access the Appendix, click on the Appendix link in the box to the right of the article online
-
To access the Appendix, click on the Appendix link in the box to the right of the article online.
-
-
-
-
8
-
-
77953432178
-
Value-based insurance design and antidiabetic medication adherence
-
Chang A, Liberman JN, Coulen C, Berger JE, Brennan TA. Value-19based insurance design and antidiabetic medication adherence. Am J Pharm Benefits. 2010;2(1):39-44.
-
(2010)
Am J Pharm Benefits
, vol.2
, Issue.1
, pp. 39-44
-
-
Chang, A.1
Liberman, J.N.2
Coulen, C.3
Berger, J.E.4
Brennan, T.A.5
-
9
-
-
38849208528
-
Impact of decreasing copayments on medication adherence within a disease management environment
-
Chernew ME, Shah MR, Wegh A, Rosenberg SN, Juster IA, Rosen AB, et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff(Millwood). 2008;27(1):103-12.
-
(2008)
Health Aff(Millwood)
, vol.27
, Issue.1
, pp. 103-12
-
-
Chernew, M.E.1
Shah, M.R.2
Wegh, A.3
Rosenberg, S.N.4
Juster, I.A.5
Rosen, A.B.6
-
10
-
-
84900365167
-
Reducing copayments for essential cardiovascular medications: evaluation of a natural experiment
-
Choudhry N, Fischer M, Liu J, Lii J, Brookhart A, Shrank W, et al. Reducing copayments for essential cardiovascular medications: evaluation of a natural experiment. J Gen Intern Med. 2010;25:S381-2.
-
(2010)
J Gen Intern Med
, vol.25
-
-
Choudhry, N.1
Fischer, M.2
Liu, J.3
Lii, J.4
Brookhart, A.5
Shrank, W.6
-
11
-
-
84867850477
-
The impact of reducing cardiovascular medication copayments on health spending and resource utilization
-
Choudhry NK, Fischer MA, Avorn JL, Lee JL, Schneeweiss S, Solomon DH, et al. The impact of reducing cardiovascular medication copayments on health spending and resource utilization. J Am Coll Cardiol. 2012;60(18):1817-24.
-
(2012)
J Am Coll Cardiol
, vol.60
, Issue.18
, pp. 1817-24
-
-
Choudhry, N.K.1
Fischer, M.A.2
Avorn, J.L.3
Lee, J.L.4
Schneeweiss, S.5
Solomon, D.H.6
-
12
-
-
84864396536
-
Medication adherence changes following value-based insurance design
-
Farley JF, Wansink D, Lindquist JH, Parker JC, Maciejewski ML. Medication adherence changes following value-1based insurance design. Am J Manag Care. 2012;18(5): 265-74.
-
(2012)
Am J Manag Care
, vol.18
, Issue.5
, pp. 265-274
-
-
Farley, J.F.1
Wansink, D.2
Lindquist, J.H.3
Parker, J.C.4
Maciejewski, M.L.5
-
13
-
-
84867715386
-
The effect of a large regional health plan's value-based insurance design program on statin use
-
Frank MB, Fendrick AM, He Y, Zbrozek A, Holtz N, Leung S, et al. The effect of a large regional health plan's value-2based insurance design program on statin use. Med Care. 2012;50(11):934-9.
-
(2012)
Med Care
, vol.50
, Issue.11
, pp. 934-939
-
-
Frank, M.B.1
Fendrick, A.M.2
He, Y.3
Zbrozek, A.4
Holtz, N.5
Leung, S.6
-
14
-
-
79951597073
-
Value-based insurance plus disease management increased medication use and produced savings
-
Gibson TB, Mahoney J, Ranghell K, Cherney BJ, McElwee N. Value-based insurance plus disease management increased medication use and produced savings. Health Aff(Millwood). 2011;30(1):100-8.
-
(2011)
Health Aff(Millwood)
, vol.30
, Issue.1
, pp. 100-108
-
-
Gibson, T.B.1
Mahoney, J.2
Ranghell, K.3
Cherney, B.J.4
McElwee, N.5
-
15
-
-
79951590391
-
A value-based insurance design program at a large company boosted medication adherence for employees with chronic illnesses
-
Gibson TB, Wang S, Kelly E, Brown C, Turner C, Frech-Tamas F, et al. A value-based insurance design program at a large company boosted medication adherence for employees with chronic illnesses. Health Aff(Millwood). 2011;30(1):109-17.
-
(2011)
Health Aff(Millwood)
, vol.30
, Issue.1
, pp. 109-117
-
-
Gibson, T.B.1
Wang, S.2
Kelly, E.3
Brown, C.4
Turner, C.5
Frech-Tamas, F.6
-
16
-
-
79952276257
-
Copayment reductions generate greater medication adherence in targeted patients
-
Maciejewski ML, Farley JF, Parker J, Wansink D. Copayment reductions generate greater medication adherence in targeted patients. Health Aff(Millwood). 2010;29(11):2002-8.
-
(2010)
Health Aff(Millwood)
, vol.29
, Issue.11
, pp. 2002-2008
-
-
Maciejewski, M.L.1
Farley, J.F.2
Parker, J.3
Wansink, D.4
-
17
-
-
77957746087
-
Prescription copay reduction program for diabetic employees
-
Nair KV, Miller K, Park J, Allen RR, Saseen JJ, Biddle V. Prescription copay reduction program for diabetic employees. Popul Health Manag. 2010;13(5):235-45.
-
(2010)
Popul Health Manag
, vol.13
, Issue.5
, pp. 235-245
-
-
Nair, K.V.1
Miller, K.2
Park, J.3
Allen, R.R.4
Saseen, J.J.5
Biddle, V.6
-
18
-
-
74049098412
-
Plan designs that encourage the use of generic drugs over brand-name drugs: an analysis of a free generic benefit
-
Rodin HA, Heaton AH, Wilson AR, Garrett NA, Plocher DW. Plan designs that encourage the use of generic drugs over brand-name drugs: an analysis of a free generic benefit. Am J Manag Care. 2009; 15(12):881-8.
-
(2009)
Am J Manag Care
, vol.15
, Issue.12
, pp. 881-888
-
-
Rodin, H.A.1
Heaton, A.H.2
Wilson, A.R.3
Garrett, N.A.4
Plocher, D.W.5
-
19
-
-
77956360952
-
The impact of value-based benefit design on adherence to diabetes medications: a propensity score-weighted difference in difference evaluation
-
Zeng F, An JJ, Scully R, Barrington C, Patel BV, Nichol MB. The impact of value-based benefit design on adherence to diabetes medications: a propensity score-weighted difference in difference evaluation. Value Health. 2010;13(6):846-52.
-
(2010)
Value Health
, vol.13
, Issue.6
, pp. 846-852
-
-
Zeng, F.1
An, J.J.2
Scully, R.3
Barrington, C.4
Patel, B.V.5
Nichol, M.B.6
-
20
-
-
79951627951
-
Value-based benefit design and healthcare utilization in asthma, hypertension, and diabetes
-
Kelly E, Turner C, Frech-Tamas F, Doyle J, Mauceri E. Value-based benefit design and healthcare utilization in asthma, hypertension, and diabetes. Am J Pharm Benefits. 2009;1(4):217-21.
-
(2009)
Am J Pharm Benefits
, vol.1
, Issue.4
, pp. 217-221
-
-
Kelly, E.1
Turner, C.2
Frech-Tamas, F.3
Doyle, J.4
Mauceri, E.5
-
21
-
-
38849208528
-
Impact of decreasing copayments on medication adherence within a disease management environment
-
Chernew ME, Shah MR, Wegh A, Rosenberg SN, Juster IA, Rosen AB, et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff(Millwood). 2008;27(1):103-12.
-
(2008)
Health Aff(Millwood)
, vol.27
, Issue.1
, pp. 103-112
-
-
Chernew, M.E.1
Shah, M.R.2
Wegh, A.3
Rosenberg, S.N.4
Juster, I.A.5
Rosen, A.B.6
-
22
-
-
82555196119
-
Full coverage for preventive medications after myocardial infarction
-
Choudhry NK, Avorn J, Glynn RJ, Antman EM, Schneeweiss S, Toscano M, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365(22):2088-97.
-
(2011)
N Engl J Med
, vol.365
, Issue.22
, pp. 2088-2097
-
-
Choudhry, N.K.1
Avorn, J.2
Glynn, R.J.3
Antman, E.M.4
Schneeweiss, S.5
Toscano, M.6
-
23
-
-
40549119813
-
Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries
-
Choudhry NK, Patrick AR, Antman EM, Avorn J, Shrank WH. Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries. Circulation. 2008;117(10):1261-8.
-
(2008)
Circulation
, vol.117
, Issue.10
, pp. 1261-1268
-
-
Choudhry, N.K.1
Patrick, A.R.2
Antman, E.M.3
Avorn, J.4
Shrank, W.H.5
-
24
-
-
22344445814
-
Cost-effectiveness of full Medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes
-
Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S. Cost-effectiveness of full Medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med. 2005;143(2):89-99.
-
(2005)
Ann Intern Med
, vol.143
, Issue.2
, pp. 89-99
-
-
Rosen, A.B.1
Hamel, M.B.2
Weinstein, M.C.3
Cutler, D.M.4
Fendrick, A.M.5
Vijan, S.6
-
25
-
-
77951522506
-
Low-value services in value-based insurance design
-
Neumann PJ, Auerbach HR, Cohen JT, Greenberg D. Low-value services in value-based insurance design. Am J Manag Care. 2010;16(4):280-6.
-
(2010)
Am J Manag Care
, vol.16
, Issue.4
, pp. 280-286
-
-
Neumann, P.J.1
Auerbach, H.R.2
Cohen, J.T.3
Greenberg, D.4
-
26
-
-
79952609487
-
What do we really know about VBID? Quality of the evidence and ethical considerations for health plan sponsors
-
Fairman KA, Curtiss FR. What do we really know about VBID? Quality of the evidence and ethical considerations for health plan sponsors. J Manag Care Pharm. 2011;17(2): 156-74.
-
(2011)
J Manag Care Pharm
, vol.17
, Issue.2
, pp. 156-74
-
-
Fairman, K.A.1
Curtiss, F.R.2
|